指南与共识炎症性肠病

AGA 中度至重度克罗恩病药物治疗临床实践指南

AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.
指南 / 共识 · Gastroenterology · 2025-01-01

美国胃肠病学会(AGA)采用 GRADE 框架制定中度至重度活动性克罗恩病(CD)的药物治疗指南,共达成 16 条推荐(1 条强推荐、9 条条件推荐、6 个知识缺口)。指南推荐多种生物制剂和小分子药物优于不治疗,并根据是否使用过高级治疗建议优先选择高效药物,同时不建议硫嘌呤单药诱导缓解,建议皮下甲氨蝶呤而非口服,以及英夫利西单抗联合硫嘌呤优于单药。

要点

  • 成人中度至重度活动性 CD 推荐英夫利西单抗、阿达木单抗、乌司奴单抗、risankizumab、mirikizumab、guselkumab 或 upadacitinib 优于不治疗。
  • 未使用过高级治疗者建议优选高效药物,而非低效药物(certolizumab pegol 或 upadacitinib)。
  • 已暴露于≥1 种高级治疗者建议优选高效或中等效药物,而非低效药物。

核心结论

  • AGA 推荐多种药物用于中度至重度活动性 CD,并根据既往高级治疗暴露选择高效或中等效药物。
  • 不建议硫嘌呤单药诱导缓解,但可用于维持缓解;建议皮下甲氨蝶呤而非口服。
  • 建议英夫利西单抗联合硫嘌呤优于英夫利西单抗单药,尤其未使用过硫嘌呤者。
  • 建议初始高级治疗优于含激素和/或免疫调节剂的阶梯治疗。

研究设计与样本

  • AGA 多学科专家组(临床专家和方法学家)采用 GRADE 框架制定本指南。
  • 工作组优先确定临床问题、识别以患者为中心的结局、进行证据合成并形成推荐。
  • 指南共达成 16 条推荐,其中 1 条强推荐、9 条条件推荐、6 个知识缺口。

主要发现

  • 成人中度至重度活动性 CD:推荐英夫利西单抗、阿达木单抗、乌司奴单抗、risankizumab、mirikizumab、guselkumab 或 upadacitinib 优于不治疗。
  • 成人中度至重度活动性 CD:建议 certolizumab pegol 或 vedolizumab 优于不治疗。
  • 未使用过高级治疗者:建议高效药物(英夫利西单抗、阿达木单抗、vedolizumab、乌司奴单抗、risankizumab、mirikizumab 或 guselkumab)而非低效药物(certolizumab pegol 或 upadacitinib)。
  • 既往暴露于≥1 种高级治疗者:建议高效药物(阿达木单抗、risankizumab、guselkumab 或 upadacitinib)或中等效药物(乌司奴单抗或 mirikizumab)而非低效药物(vedolizumab 或 certolizumab pegol)。

关键数值与推荐

  • 成人中度至重度活动性 CD 门诊患者:建议反对硫嘌呤单药诱导缓解。
  • 成人中度至重度活动性 CD:建议硫嘌呤单药优于不治疗用于维持(通常为激素诱导的)缓解。
  • 建议使用皮下甲氨蝶呤诱导和维持缓解,反对使用口服甲氨蝶呤。
  • 建议英夫利西单抗联合硫嘌呤优于英夫利西单抗单药,尤其未使用过硫嘌呤者。
  • 建议初始高级治疗优于含激素和/或免疫调节剂的阶梯治疗。

临床怎么用

  • 临床选择药物时需考虑患者既往是否暴露于高级治疗,以选择高效或中等效药物。
  • 诱导缓解避免使用硫嘌呤单药;维持缓解可考虑硫嘌呤单药。
  • 甲氨蝶呤应选择皮下给药而非口服。
  • 英夫利西单抗可考虑联合硫嘌呤,尤其未使用过硫嘌呤者。
  • 对中度至重度活动性 CD 可考虑初始高级治疗而非阶梯治疗。

局限性

  • 指南识别了 6 个知识缺口,并提出了未来研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacologic management of moderate-to-severely active Crohn's disease (CD). METHODS: A multidisciplinary panel of clinical experts and methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations. RESULTS: The guideline panel agreed on 16 recommendations, of which 1 is a strong recommendation, 9 are conditional recommendations, and 6 were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests the use of certolizumab pegol or vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower-efficacy medication (certolizumab pegol or upadacitinib). In individuals who have previously been exposed to 1 or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, or upadacitinib) or intermediate efficacy medication (ustekinumab or mirikizumab) rather than a lower efficacy medication (vedolizumab or certolizumab pegol). In adult outpatients with moderate-to-severely active CD, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests using subcutaneous methotrexate for induction and maintenance of remission, but suggests against using oral methotrexate. The AGA suggests using combination therapy with infliximab and thiopurines over infliximab monotherapy, particularly in those naïve to thiopurines. The AGA also suggests using initial advanced therapy over step therapy involving corticosteroids and/or immunomodulators in patients with moderate-to-severely active CD. The panel also proposed key implementation considerations for optimal use of these medications, identified several knowledge gaps, and areas for future research. CONCLUSIONS: This guideline provides a comprehensive, patient-centered, evidence-based approach to the pharmacologic management of patients with moderate-to-severely active CD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Scott FI, Ananthakrishnan AN, Click B, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology. 2025. PMID: 41274746. doi:10.1053/j.gastro.2025.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。